Shenyang Xingqi Pharmaceutical Co.,Ltd (300573.SZ)
CNY 77.66
(-1.03%)
CNY 77.66
(-1.03%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 333.92 Million CNY | 44.79% |
| 2022 | 230.63 Million CNY | -32.63% |
| 2021 | 342.35 Million CNY | 26.03% |
| 2020 | 271.64 Million CNY | -2.1% |
| 2019 | 277.46 Million CNY | 80.3% |
| 2018 | 153.89 Million CNY | 25.02% |
| 2017 | 123.09 Million CNY | -38.6% |
| 2016 | 200.46 Million CNY | -23.24% |
| 2015 | 261.14 Million CNY | -13.84% |
| 2014 | 303.08 Million CNY | 31.55% |
| 2013 | 230.4 Million CNY | 80.97% |
| 2012 | 127.31 Million CNY | 509.68% |
| 2011 | 20.88 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 558 Million CNY | 9.34% |
| 2024 Q1 | 386.83 Million CNY | 15.85% |
| 2024 Q2 | 510.33 Million CNY | 31.93% |
| 2023 Q3 | 323.67 Million CNY | 10.39% |
| 2023 Q4 | 333.92 Million CNY | 3.17% |
| 2023 FY | 333.92 Million CNY | 44.79% |
| 2023 Q1 | 250.01 Million CNY | 8.4% |
| 2023 Q2 | 293.21 Million CNY | 17.28% |
| 2022 Q3 | 269.84 Million CNY | 18.97% |
| 2022 Q2 | 226.81 Million CNY | -12.75% |
| 2022 Q1 | 259.95 Million CNY | -24.07% |
| 2022 Q4 | 230.63 Million CNY | -14.53% |
| 2022 FY | 230.63 Million CNY | -32.63% |
| 2021 Q2 | 308.63 Million CNY | -1.55% |
| 2021 Q4 | 342.35 Million CNY | 9.77% |
| 2021 Q1 | 313.5 Million CNY | 15.41% |
| 2021 FY | 342.35 Million CNY | 26.03% |
| 2021 Q3 | 311.87 Million CNY | 1.05% |
| 2020 Q4 | 271.64 Million CNY | -9.26% |
| 2020 FY | 271.64 Million CNY | -2.1% |
| 2020 Q2 | 267.42 Million CNY | 18.47% |
| 2020 Q1 | 225.72 Million CNY | -18.65% |
| 2020 Q3 | 299.36 Million CNY | 11.94% |
| 2019 Q2 | 247.56 Million CNY | 61.76% |
| 2019 FY | 277.46 Million CNY | 80.3% |
| 2019 Q1 | 153.04 Million CNY | -0.55% |
| 2019 Q4 | 277.46 Million CNY | 6.38% |
| 2019 Q3 | 260.81 Million CNY | 5.35% |
| 2018 Q1 | 117.86 Million CNY | -4.24% |
| 2018 Q4 | 153.89 Million CNY | 6.25% |
| 2018 FY | 153.89 Million CNY | 25.02% |
| 2018 Q3 | 144.84 Million CNY | 1.05% |
| 2018 Q2 | 143.33 Million CNY | 21.6% |
| 2017 Q2 | 117.24 Million CNY | -14.16% |
| 2017 Q3 | 121.5 Million CNY | 3.63% |
| 2017 Q4 | 123.09 Million CNY | 1.31% |
| 2017 FY | 123.09 Million CNY | -38.6% |
| 2017 Q1 | 136.58 Million CNY | -31.87% |
| 2016 Q1 | - CNY | 0.0% |
| 2016 FY | 200.46 Million CNY | -23.24% |
| 2016 Q4 | 200.46 Million CNY | -4.55% |
| 2016 Q3 | 210.02 Million CNY | -5.72% |
| 2016 Q2 | 222.75 Million CNY | 0.0% |
| 2015 FY | 261.14 Million CNY | -13.84% |
| 2014 Q4 | 303.08 Million CNY | 1.06% |
| 2014 FY | 303.08 Million CNY | 31.55% |
| 2014 Q3 | 299.91 Million CNY | 0.0% |
| 2013 FY | 230.4 Million CNY | 80.97% |
| 2012 FY | 127.31 Million CNY | 509.68% |
| 2011 FY | 20.88 Million CNY | 0.0% |